LOS ANGELES, CA--(Marketwire - February 10, 2010) -
| Highlighted Links |
|
|
BioMedReports.Com, the news portal which covers Wall Street’s biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, is reporting that Rexahn Pharmaceuticals (NYSE Amex: RNN) has gone almost completely undiscovered by most investors in the space of thousands of publicly traded biotechnology and health care companies. Until now.
In short, this is a clinical stage biopharmaceutical company trading under a dollar on a major exchange, with multiple catalysts to help its share price move significantly higher in the short term (this quarter). The potential of the treatments and drugs in the company’s pipeline include three drugs that analysts have labled “potential blockbusters” that have several big pharmaceutical companies lining up as interested partners.
In fact, already one partner -- Teva Pharmaceuticals -- signed a development & commercialization agreement for RX-3117, a novel anti-cancer compound last September.
RNN also has “multi-indication” therapeutics that positions it for long-term success. Their three market leading compounds have all shown excellent safety profiles.
A complete report on the company with quotes from its CEO and founder, Dr. Chang Ahn is available now at BioMedReports.Com:
Biotech investors interested in accessing the news portal’s complete database of clinical trials and upcoming FDA decisions can access that information here:
http://biomedreports.com/fda-calendar/fda-calendar.html
About BioMedReports.Com
BioMedReports.Com is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report news and developments about publicly traded companies.
For more biomedical sector and investment news go to http://BioMedReports.com
Media Contact:
Mary Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact
Tel: +1 323 472 4480
Fax: +1 888 210 3556
